StocksTevogen Resolves Nasdaq Compliance Issue
Latest
HSBC Raises Gilead Target to $175 Amid Mixed Analyst Views
HSBC lifted its price target for Gilead Sciences to $175, citing strong Q2 revenue performance despite other firms lowering their expectations.
Unicycive Faces Class Action After FDA Rejection
Unicycive Therapeutics is under legal scrutiny following a 39% stock drop triggered by the FDA's rejection of its kidney disease drug resubmission.
Salazar Discloses SpaceX and Berkshire Trades
Rep. Salazar disclosed purchases in SpaceX and Berkshire Hathaway, alongside a same-day Moderna trade coinciding with a Phase 3 vaccine announcement.
Vertex Q2 Revenue Beats Estimates as Peer Group Outperforms
Vertex Pharmaceuticals posted a 12.5% revenue increase, outpacing sector expectations while peers showed mixed results in the latest therapeutics earnings cycle.
Cardinal Health Q4 Earnings Beat Estimates Despite Revenue Miss
Cardinal Health delivered a strong fourth-quarter performance with adjusted earnings per share of $2.91, significantly exceeding market expectations, even as total revenues fell short of consensus targets.
Roivant Shares Rise on Pulmonary Hypertension Data
Roivant Sciences shares climbed following positive clinical results for its pulmonary hypertension therapy, shifting investor focus to the durability of its clinical pipeline and commercial execution capabilities.
Cooper Companies posts record cash flow and tax benefit
The Cooper Companies reported record free cash flow and a significant tax benefit, offsetting headwinds from inventory adjustments in its vision care division.
Intuitive Surgical Faces $110 Downside Risk Amid Volatility
Intuitive Surgical stock trades at a significant discount to its highs while options markets price in substantial volatility, reflecting ongoing uncertainties in procedure growth and instrument costs.
J&J and AbbVie Post Resilient Earnings Amid Market Volatility
Johnson & Johnson and AbbVie report strong quarterly performance, driven by oncology and immunology growth, while maintaining dividend payouts.
Axsome Q2 Revenue Misses Expectations Despite Auvelity Growth
Axsome Therapeutics reported second-quarter revenues of $218.4 million, missing consensus estimates despite a 46% year-over-year increase driven by its lead product, Auvelity.
BridgeBio Pharma Q2 Sales Beat Estimates Despite Loss
BridgeBio Pharma shares fell 10.7% after Q2 results showed a wider-than-expected loss, even as Attruby sales tripled year-over-year.
Telix Faces FDA Decision Amid TGA Maggot Therapy Rule Changes
Telix Pharmaceuticals faces a critical FDA deadline for its glioma imaging agent, while Australian regulators ease requirements for maggot debridement therapy and diagnostic firms report lab progress.
More
Illustration: Tradingbird United Therapeutics Q2 Revenue Beats Estimates
United Therapeutics outperformed consensus in Q2, though stock lags peers as Myriad Genetics posts sharp decline.
Illustration: Tradingbird Capricor Faces Securities Suit Over Dermamiocel Plan Changes
A class action alleges Capricor misled investors regarding its statistical analysis plan for Dermamiocel, leading to a 64% stock drop.
Illustration: Tradingbird Alpha Cognition Issues 25,000 Inducement Options to New Hire
Alpha Cognition granted 25,000 stock options to a new non-executive employee under Nasdaq Rule 5635(c)(4), with an exercise price set at the September 8 closing rate.
Illustration: Tradingbird Cooper and Kewaunee Lead Post-Market Healthcare Moves
Cooper Companies and Kewaunee Scientific drove significant volatility in Wednesday's after-market session, with both names declining sharply following earnings releases.
Illustration: Tradingbird Rocket Pharmaceuticals Q2 Results Show Losses Narrowing
Rocket Pharmaceuticals reported a quarter with zero revenue but significantly reduced operating expenses, driven by cost cuts in legal and R&D. The company’s cash position expanded sharply due to a regulatory voucher sale, offsetting the lack of product sales.
Illustration: Tradingbird Theravance Bio Q2 Results Show Revenue Slump
Theravance Bio posted a profit on sharply lower costs, but core revenue declined 21% year-over-year as it winds down clinical trials.
Illustration: Tradingbird BridgeBio Infigratinib Data Shows Respiratory and Metabolic Benefits
New clinical data for infigratinib indicates improvements in sleep apnea, ear infections, and body composition for children with achondroplasia, supporting a mid-2027 US launch.
Illustration: Tradingbird Pacira BioSciences issues inducement equity grants to five new hires
Pacira BioSciences disclosed the grant of stock options and restricted stock units to five new employees under Nasdaq Rule 5635(c)(4), with vesting schedules tied to continued service.
Illustration: Tradingbird X4 Pharmaceuticals Sets September Investor Meeting
X4 Pharmaceuticals will host a fireside chat at the 2026 Wells Fargo Healthcare Conference to discuss its pipeline and commercial strategy.
Illustration: Tradingbird Oil Prices Pressure Stocks Amid Fed Rate Hike Fears
US equities are under pressure as Brent crude tops $100 following the US military's confirmation of strikes on Iranian tankers, simultaneously boosting Fed rate hike odds to 60%. Investors are now turning their attention to Apple’s first keynote under CEO John Ternus, where a foldable iPhone launch is highly anticipated.